RARE CANCERS & SARCOMA
Tailored combinations of tools are the way forward to assess quality of life in rare cancers
Recent studies emphasise that the current approach does not fully capture the needs and experiences of patients with rare tumours
New immunotherapy option emerges for low-risk gestational trophoblastic neoplasia
Adding first-line checkpoint inhibition to standard treatment shows promise to improve response in women
Why clinical practice guidelines matter even more in rare cancers
A recent EURACAN survey highlights a high uptake of recommendations from medical oncologists, potentially leading to improved patients’ survival
ESMO LATEST RECOMMENDATIONS
How to close the age gap in clinical cancer research?
From geriatric assessment to artificial intelligence, an ESMO/SIOG paper highlights effective strategies to improve the representation of older patients in clinical trials
Structured exercise enters ESMO guidelines for colon cancer as recommended treatment
The update reflects survival benefits of post-diagnosis exercise in stage II–III colon cancer as recently reported in the CHALLENGE study
The first ESMO guidance for AI-based biomarkers
In a newly released framework paper, ESMO defines criteria for assessing and implementing AI-based biomarkers in oncology
AI & DIGITAL ONCOLOGY
Research unlocks insights into lung cancer evolution from electronic medical records
A domain-specific natural language processing (NPL) pipeline showed strong performance in extracting clinically meaningful information from diverse clinical documents of patients with non-small cell lung cancer
Trustworthy and explainable AI – a key to equitable oncology?
Mitigating research biases by rigorous data analysis and validation can pave the way for a wider adoption of artificial intelligence in cancer care
Study supports radiomics in predicting immunotherapy effectiveness in advanced NSCLC
In a real-world study, multimodal artificial intelligence models outperform PD-L1 across key endpoints
OPINIONS
The challenge of undifferentiated sarcomas
Pawel Sobczuk
Sex and gender are key for precision oncology and benefit all patients
Berna Özdemir
The power of dual-layer genomics in precision oncology
Umberto Malapelle
Shaping the use of AI in oncology
Jakob N. Kather
Artificial intelligence is expediting the development of therapeutic immunotherapies
Sine Reker Hadrup
OPINIONS
The challenge of undifferentiated sarcomas
Pawel Sobczuk
Sex and gender are key for precision oncology and benefit all patients
Berna Özdemir
The power of dual-layer genomics in precision oncology
Umberto Malapelle
Shaping the use of AI in oncology
Jakob N. Kather
Artificial intelligence is expediting the development of therapeutic immunotherapies
Sine Reker Hadrup